NCT02465060: Phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With RRMM
- Active, not recruiting
- Dec 10, 2015
- 4 min read
Updated: Feb 10, 2024
NCT02465060: phase 2: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Sponsor
ClinicalTrials.gov Identifier: NCT02465060
Official Title: Molecular Analysis for Therapy Choice (MATCH)
First Posted: June 8, 2015
Click here for details on ClinicalTrials.gov
Drug: Adavosertib
Drug: Afatinib
Drug: Afatinib Dimaleate
Drug: Binimetinib
Drug: Capivasertib
Drug: Copanlisib
Drug: Copanlisib Hydrochloride
Drug: Crizotinib
Other: Cytology Specimen Collection Procedure
Drug: Dabrafenib
Drug: Dabrafenib Mesylate
Drug: Dasatinib
Drug: Defactinib
Drug: Defactinib Hydrochloride
Drug: Erdafitinib
Drug: FGFR Inhibitor AZD4547
Drug: Ipatasertib
Other: Laboratory Biomarker Analysis
Drug: Larotrectinib
Drug: Larotrectinib Sulfate
Biological: Nivolumab
Drug: Osimertinib
Drug: Palbociclib
Biological: Pertuzumab
Drug: PI3K-beta Inhibitor GSK2636771
Biological: Relatlimab
Drug: Sapanisertib
Drug: Sunitinib Malate
Drug: Taselisib
Drug: Trametinib
Biological: Trastuzumab
Biological: Trastuzumab Emtansine
Drug: Ulixertinib
Drug: Vismodegib
Locations
United States, Alabama
United States, Alaska
United States, Arizona
United States, Arkansas
United States, California
United States, Colorado
United States, Connecticut
United States, Delaware
United States, District of Columbia
United States, Florida
United States, Georgia
United States, Hawaii
United States, Idaho
United States, Illinois
United States, Indiana
United States, Iowa
United States, Kansas
United States, Kentucky
United States, Louisiana
United States, Maine
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Mississippi
United States, Missouri
United States, Montana
United States, Nebraska
United States, Nevada
United States, New Jersey
United States, New Mexico
United States, New York
United States, North Carolina
United States, North Dakota
United States, Ohio
United States, Oklahoma
United States, Oregon
United States, Pennsylvania
United States, Rhode Island
United States, South Carolina
United States, South Dakota
United States, Tennessee
United States, Texas
United States, Utah
United States, Vermont
United States, Virginia
United States, Washington
United States, West Virginia
United States, Wisconsin
United States, Wyoming
Guam
Puerto Rico
Other ECOG Trials
NCT04566328: Phase 3 - EAA181 / EQUATE - Testing the Use of Combination Therapy in NDMM
NCT03937635: Phase 3 - EAA173 / DETER-SMM - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma
NCT03941860: Phase 3 - EAA171 / OPTIMUM - Addition of Ixazomib to Lenalidomide in Patients With Residual Myeloma
NCT02465060: Phase 2 - EAY131 / NCI-MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
